徳島大学 教育・研究者情報データベース(EDB)

1. (英) Sawada Akihisa

   役割	任意
   貢献度	任意
   学籍番号	推奨

2. (英) Ohga Shouichi

   役割	任意
   貢献度	任意
   学籍番号	推奨

3. (英) Ishii Eiichi

   役割	任意
   貢献度	任意
   学籍番号	推奨

4. (英) Inoue Masami

   役割	任意
   貢献度	任意
   学籍番号	推奨

5. (英) Okada Keiko

   役割	任意
   貢献度	任意
   学籍番号	推奨

6. (英) Inagaki Jiro

   役割	任意
   貢献度	任意
   学籍番号	推奨

7. (英) Goto Hiroaki

   役割	任意
   貢献度	任意
   学籍番号	推奨

8. (英) Suzuki Nobuhiro

   役割	任意
   貢献度	任意
   学籍番号	推奨

9. (英) Koike Kazutoshi

   役割	任意
   貢献度	任意
   学籍番号	推奨

10. (英) Atsuta Yoshiko

    役割	任意
    貢献度	任意
    学籍番号	推奨

11. (英) Suzuki Ritsuro

    役割	任意
    貢献度	任意
    学籍番号	推奨

12. (英) Yabe Hiromasa

    役割	任意
    貢献度	任意
    学籍番号	推奨

13. (英) Kawa Keisei

    役割	任意
    貢献度	任意
    学籍番号	推奨

14. (英) Kato Koji

    役割	任意
    貢献度	任意
    学籍番号	推奨

15. 安友 康二([徳島大学.大学院医歯薬学研究部.医学域.医科学部門.病理系.生体防御医学])

    役割	任意
    貢献度	任意
    学籍番号	推奨

(英) Feasibility of reduced-intensity conditioning followed by unrelated cord blood transplantation for primary hemophagocytic lymphohistiocytosis: a nationwide retrospective analysis in Japan.

(日) A nationwide retrospective analysis was performed on patients who received allogeneic hematopoietic stem cell transplantation for primary or familial hemophagocytic lymphohistiocytosis (HLH) in Japan. The present analysis investigated whether reduced-intensity conditioning (RIC) followed by cord blood transplantation (CBT) (RIC-CBT) is feasible, compared to the outcomes of myeloablative conditioning and bone marrow transplantation. Based on the JSHCT data, 53 patients were analyzed. The overall survival rate (OS) was 65.4 ± 6.6 %. RIC-CBT (n = 13) was not inferior to other methods. Patients with a performance status of PS 4 (ECOG scale) with HLH-associated severe organ dysfunction during the initiation of conditioning had extremely poor outcomes. The OS rate in the RIC-CBT patients, excluding those with a performance status 4, was 80.0 ± 12.6 %. RIC may reduce treatment-related mortality; in addition, patients with engraftment failure, which is the main adverse event following RIC-CBT, were successfully rescued with secondary CBT. Unrelated cord blood may represent an alternative source if a patient has no related donor. As a RIC regimen for CBT, 140 mg/m(2) melphalan with fludarabine and anti-lymphocyte globulin or anti-thymocyte globulin may be feasible, but further dosage optimization should be performed in controlled clinical trials.

1. (英) Adolescent
2. (英) Allografts
3. (英) Antilymphocyte Serum
4. (英) Child
5. (英) Child, Preschool
6. (英) Cord Blood Stem Cell Transplantation
7. (英) Disease-Free Survival
8. (英) Female
9. (英) Humans
10. (英) Immunosuppressive Agents
11. (英) Infant
12. (英) Japan
13. (英) Lymphohistiocytosis, Hemophagocytic
14. (英) Male
15. (英) Melphalan
16. (英) Myeloablative Agonists
17. (英) Survival Rate
18. (英) Transplantation Conditioning
19. (英) Unrelated Donors
20. (英) Vidarabine

1. (英) PublicationType: Clinical Trial

2. (英) PublicationType: Journal Article

3. (英) PublicationType: Multicenter Study

4. (英) PublicationType: Research Support, Non-U.S. Gov't